boiron sa (BOI:EN Paris)

Last €40.76 EUR

Change Today -0.26 / -0.63%

Volume 4.6K

BOI On Other Exchanges

Symbol

Exchange

BOI:FP

EN Paris

BOIRF:US

OTC US

BON:GR

Frankfurt

As of 8:46 AM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

boiron sa (BOI) Snapshot

Open €40.87		Previous Close €41.02
Day High €40.96		Day Low €40.51
52 Week High 04/3/13 - €43.98		52 Week Low 06/6/12 - €19.31
Market Cap 792.4M		Average Volume 10 Days 9.2K
EPS TTM €2.33		Shares Outstanding 19.4M
EX-Date 05/31/13		P/E TM 17.5x
Dividend €0.90		Dividend Yield 1.72%

BOI:FP Historical Stock Quote
BOI:FP Advanced Stock Chart

Related News

No related news articles were found.

boiron sa (BOI) Related Businessweek News

No Related Businessweek News Found

boiron sa (BOI) Details

Boiron SA, a pharmaceutical company, together with its subsidiaries, engages in the development, manufacture, and marketing of nonproprietary homeopathic medicines and OTC medication specialties. It offers homeopathic medicines in two family groups, including medicines associated with precise therapeutic indications and dosage in the form of tablets, syrups, single-dose liquids, ointments, and other presentations; and medicines that do not mention a therapeutic indication or dosage in the form of tubes, granular tubes, and cellular doses. The company produces its medicines by using vegetable, animal, mineral, and chemical substances. It primarily operates in France, rest of Europe, and North America. Boiron SA was founded in 1932 and is headquartered in Sainte Foy-les-Lyon, France.

Detailed BOI:FP Company Description...

www.boiron.com

3,792 Employees
Last Reported Date: 04/12/13

Founded in 1932

boiron sa (BOI) Top Compensated Officers

Philippe Montant

Finance & Administration Director and Deputy ...

Age: 49

Total Annual Compensation: €154.3K

Mr. Philippe Gouret

Chief Pharmacist, Director of Production & Di...

Age: 56

Total Annual Compensation: €250.4K

Mr. Christian Boiron

General Manager and Director

Age: 64

Total Annual Compensation: €516.0K

Executives, Board Directors

Compensation as of Fiscal Year 2011.

boiron sa (BOI) Key Developments

Boiron SA Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2012; Proposes Divided, Payable on June 5, 2013; Provides Earnings Guidance for the First Quarter and Full Year of 2013

Mar 13 13

Boiron SA announced audited consolidated earnings results for the year ended December 31, 2012. For the year, the company reported sales of EUR 566,294,000 compared to EUR 523,215,000 a year ago. Operating income was EUR 81,109,000 compared to EUR 63,695,000 a year ago. Net income-group share was EUR 49,626,000 compared to EUR 42,248,000 a year ago. The profitability has improved due in particular to the price increase of certain non proprietary medicines in France and the control of operating costs. The Board of Directors will propose to the Combined Shareholders Meeting the distribution of a dividend of 0.90 per share. The payment of the dividend will be June 5, 2013. In the first quarter of 2013, the business is expected to grow significantly due to the high level of winter pathology. In 2013, the company targets a new increase of its turnover and profitability.

Boiron SA, 2012 Earnings Call, Mar 14, 2013

Mar 8 13

Boiron SA, 2012 Earnings Call, Mar 14, 2013

Boiron SA Presents at Oddo MidCap Forum 2013, Jan-10-2013

Nov 27 12

Boiron SA Presents at Oddo MidCap Forum 2013, Jan-10-2013 . Venue: Lyon Convention Center, 50 quai Charles de Gaulle, 69006 Lyon, France. Speakers: Véronique BOUSCAYROL, Group Accounting Director.